Antimicrobial peptides: Therapeutic potential

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 6, 2006, Pages 653-663

  Zhang, Lijuan ^a   Falla, Timothy J ^a  

^a Helix Biomedix Inc   (United States)

Author keywords

Antimicrobial peptides; Commercialisation; Host defence; Immumodulatory; Innate immunity; Topical anti infectives

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; AROMATIC AMIDE; CATIONIC STEROID ANTIBIOTIC AGENT; CECROPIN; CZEN 002; DEMEGEL; GRANULYSIN DERIVATIVE; HB 107; HISTATIN DERIVATIVE; INDOLICIDIN DERIVATIVE; ISEGENAN; LACTOFERRIN DERIVATIVE; MBI 226; MBI 594; MBI 594AN; MELITTIN; MX 226; NOVICIDIN; OMIGANAN PENTACHLORIDE; PEPTIDE DERIVATIVE; PEXIGANAN ACETATE; PLECTASIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN; PTX 001; PTX 002; PTX 003; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; TALACTOFERRIN; TOPICAL ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACNE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; BURN; CANCER; CATHETER INFECTION; CLINICAL TRIAL; COST CONTROL; CYSTIC FIBROSIS; DERMATOLOGY; DIABETIC FOOT; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; GRAM NEGATIVE INFECTION; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION CONTROL; INFLAMMATION; LUNG NON SMALL CELL CANCER; MOUTH HYGIENE; NONHUMAN; ORAL MUCOSAL DISEASE; PROBABILITY; REVIEW; SKIN LEISHMANIASIS; THRUSH; VAGINA CANDIDIASIS; WOUND HEALING;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645803815     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.6.653     Document Type: Review

References (89)

1. REDDY KV, YEDERY RD, ARANHA C: Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents (2004) 24(6):536-547.
2. TOKE O: Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers (2005) 80(6):717-735.
3. OTVOS L Jr: Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci. (2005) 11(11):697-706.
4. ZHANG L, PARENTE J, HARRIS SM et al.: Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. (2005) 49(7):2921-2927.
5. ZHANG L, FALLA TJ: Cationic antimicrobial peptides - an update. Expert Opin. Investig. Drugs (2004) 13(2):97-106.
6. SELSTED ME, OUELLETTE AJ: Mammalian defensins in the antimicrobial immune response. Nat. Immunol. (2005) 6(6):551-557.
7. SCHNEIDER JJ, UNHOLZER A, SCHALLER M, SCHAFER-KORTING M, KORTING HC: Human defensins. J. Mol. Med. (2005) 83(8):587-595.
8. PATIL A, HUGHES AL, ZHANG G: Rapid evolution and diversification of mammalian α-defensins as revealed by comparative analysis of rodent and primate genes. Physiol. Genomics (2004) 20(1):1-11.
9. RADHAKRISHNAN Y, HAMIL KG, YENUGU S et al.: Identification, characterisation, and evolution of a primate β-defensin gene cluster. Genes Immun. (2005) 6(3):203-210.
10. NGUYEN TX, COLE AM, LEHRER RI: Evolution of primate θ-defensins: a serpentine path to a sweet tooth. Peptides (2003) 24(11):1647-1654.
11. COLE AM, HONG T, BOO LM et al.: Retrocyclin: a primate peptide that protects cells from infection by T and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA (2002) 99(4):1813-1818.
12. ZANETTI M, GENNARO R, ROMEO D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. (1995) 374(1):1-5.
13. NIZET V, GALLO RL: Cathelicidins and innate defence against invasive bacterial infection. Scand. J. Infect. Dis. (2003) 35(9):670-676.
14. PARK CH, VALORE EV, WARING AJ, GANZ T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. (2001) 276(11):7806-7810.
15. RIEG S, GARBE C, SAUER B, KALBACHER H, SCHITTEK B: Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. Br. J. Dermatol. (2004) 151(3):534-539.
16. OPPENHEIM FG, XU T, MCMILLIAN FM et al.: Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J. Biol. Chem. (1988) 263(16):7472-7477.
17. GORDON YJ, HUANG LC, ROMANOWSKI EG et al.: Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. (2005) 30(5):385-394.
18. MCINTOSH RS, CADE JE, AL-ABED M et al.: The spectrum of antimicrobial peptide expression at the ocular surface. Invest. Ophthalmol. Vis. Sci. (2005) 46(4):1379-1385.
19. BERGMAN P, TERMEN S, JOHANSSON L et al.: The antimicrobial peptide rCRAMP is present in the central nervous system of the rat. J. Neurochem. (2005) 93(5):1132-1140.
20. FLAD T, BOGUMIL R, TOLSON J et al.: Detection of dermcidin-derived peptides in sweat by ProteinChip technology. J. Immunol. Methods (2002) 270(1):53-62.
21. BARDAN A, NIZET V, GALLO RL: Antimicrobial peptides and the skin. Expert Opin. Biol. Ther. (2004) 4(4):543-549.
22. SORENSEN OE, THAPA DR, ROSENTHAL A et al.: Differential regulation of β-defensin expression in human skin by microbial stimuli. J. Immunol. (2005) 174(8):4870-4879.
23. CHEN X, NIYONSABA F, USHIO H et al.: Synergistic effect of antibacterial agents human β-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J. Dermatol. Sci. (2005) 40(2):123-132.
24. LOPEZ-GARCIA B, LEE PH, YAMASAKI K, GALLO RL: Antifungal activity of cathelicidins and their potential role in Candida albicans skin infection. J. Invest. Dermatol. (2005) 125(1):108-115.
25. NIZET V, OHTAKE T, LAUTH X et al.: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature (2001) 414(6862):454-457.
26. LEE PH, OHTAKE T, ZAIOU M et al.: Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. Proc. Natl. Acad. Sci. USA (2005) 102(10):3750-3755.
27. RIEG S, STEFFEN H, SEEBER S et al.: Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defence of human skin in vivo. J. Immunol. (2005) 174(12):8003-8010.
28. HOWELL MD, JONES JF, KISICH KO et al.: Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. (2004) 172(3):1763-1767.
29. MCINTURFF JE, WANG SJ, MACHLEIDT T et al.: Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against Propionibacterium acnes. J. Invest. Dermatol. (2005) 125(2):256-263.
30. STEINSTRAESSER L, KLEIN RD, AMINLARI A et al.: Protegrin-1 enhances bacterial killing in thermally injured skin. Crit. Care Med. (2001) 29(7):1431-1437.
31. CHALEKSON CP, NEUMEISTER MW, JAYNES J: Improvement in burn wound infection and survival with antimicrobial peptide D2A21 (Demegel). Plast. Reconstr. Surg. (2002) 109(4):1338-1343.
32. CARRETERO M, DEL RIO M, GARCIA M et al.: A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. FASEB J. (2004) 18(15):1931-1933.
33. MANGONI ML, SAUGAR JM, DELLISANTI M et al.: Temporins, small antimicrobial peptides with leishmanicidal activity. J. Biol. Chem. (2005) 280(2):984-990.
34. ALBEROLA J, RODRIGUEZ A, FRANCINO O et al.: Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob. Agents Chemother. (2004) 48(2):641-643.
35. DALE BA, FREDERICKS LP: Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr. Issuets. Mol. Biol. (2005) 7(2):119-133.
36. VANKEERBERGHEN A, NUYTTEN H, DIERICKX K et al.: Differential induction of human β-defensin expression by periodontal commensals and pathogens in periodontal pocket epithelial cells. J. Periodontol. (2005) 76(8):1293-1303.
37. OUHARA K, KOMATSUZAWA H, YAMADA S et al.: Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. (2005) 55(6):888-896.
38. TAO R, JUREVIC RJ, COULTON KK et al.: Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob. Agents Chemother. (2005) 49(9):3883-3888.
39. TANIDA T, OKAMOTO T, OKAMOTO A et al.: Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. J. Oral Pathol. Med. (2003) 32(10):586-594.
40. MEYER JE, HARDER J, GOROGH T et al.: Human β-defensin-2 in oral cancer with opportunistic Candida infection. Anti-Cancer Res. (2004) 24(2B):1025-1030.
41. PUTSEP K, CARLSSON G, BOMAN HG, ANDERSSON M: Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet (2002) 360(9340):1144-1149.
42. GILES FJ, RODRIGUEZ R, WEISDORF D et al.: A Phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk. Res. (2004) 28(6):559-565.
43. PAQUETTE DW, SIMPSON DM, FRIDEN P, BRAMAN V, WILLIAMS RC: Safety and clinical effects of topical histatin gels in humans with experimental gingivitis. J. Clin. Periodontol. (2002) 29(12):1051-1058.
44. PAQUETTE DW, WATERS GS, STEFANIDOU VL et al.: Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins. J. Clin. Periodontol. (1997) 24(4):216-222.
45. YOSHINARI M, KATO T, MATSUZAKA K et al.: Adsorption behavior of antimicrobial peptide histatin 5 on PMMA. J. Biomed. Mater. Res. B Appl. Biomater. (2005) 77B(1):47-54.
46. ASHITANI J, MUKAE H, ARIMURA Y et al.: High concentrations of α-defensins in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Life Sci. (2004) 75(9):1123-1134.
47. ROSS DJ, COLE AM, YOSHIOKA D et al.: Increased bronchoalveolar lavage human β-defensin Type 2 in bronchiolitis obliterans syndrome after lung transplantation. Transplantation (2004) 78(8):1222-1224.
48. SHELLITO JE: Failure of host defences in human immunodeficiency virus. Semin. Respir. Crit. Care Med. (2004) 25(1):73-84.
49. BALS R, WANG X, WU Z et al.: Human β-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Invest. (1998) 102(5):874-880.
50. BALS R, WEINER DJ, MOSCIONI AD, MEEGALLA RL, WILSON JM: Augmentation of innate host defence by expression of a cathelicidin antimicrobial peptide. Infect. Immun. (1999) 67(11):6084-6089.
51. MYGIND PH, FISCHER RL, SCHNORR KM et al.: Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature (2005) 437(7061):975-980.
52. WESTERMAN EM, LE BRUN PP, TOUW DJ, FRIJLINK HW, HEIJERMAN HG: Effect of nebulized colistin sulfate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J. Cyst. Fibros. (2004) 3(1):23-28.
53. OUELLETTE AJ: Defensin-mediated innate immunity in the small intestine. Best Pract Res. Clin. Gastroenterol. (2004) 18(2):405-419.
54. VORA P, YOUDIM A, THOMAS LS et al.: β-defensin-2 expression is regulated by TLR signalling in intestinal epithelial cells. J. Immunol. (2004) 173(9):5398-5405.
55. ISOMOTO H, MUKAE H, ISHIMOTO H et al.: High concentrations of human β-defensin 2 in gastric juice of patients with Helicobacter pylori infection. World J. Gastroenterol. (2005) 11(31):4782-4787.
56. WEHKAMP J, SALZMAN NH, PORTER E et al.: Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. USA (2005) 102(50):18129-18134.
57. ECKMANN L: Defence molecules in intestinal innate immunity against bacterial infections. Curr. Opin. Gastroenterol. (2005) 21(2):147-151.
58. IIMURA M, GALLO RL, HASE K et al.: Cathelicidin mediates innate intestinal defence against colonization with epithelial adherent bacterial pathogens. J. Immunol. (2005) 174(8):4901-4907.
59. SALZMAN NH, GHOSH D, HUTTNER KM, PATERSON Y, BEVINS CL: Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 422(6931):522-526.
60. WIRA CR, FAHEY JV, SENTMAN CL, PIOLI PA, SHEN L: Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol. Rev. (2005) 206:306-335.
61. JOHN M, KELLER MJ, FAM EH et al.: Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J. Infect. Dis. (2005) 192(10):1731-1740.
62. PIVARCSI A, NAGY I, KORECK A et al.: Microbial compounds induce the expression of pro-inflammatory cytokines, chemokines and human β-defensin-2 in vaginal epithelial cells. Microbes Infect. (2005) 7(9-10):1117-1127.
63. BERGMAN P, JOHANSSON L, ASP V et al.: Neisseria gonorrhoeae downregulates expression of the human antimicrobial peptide LL-37. Cell Microbiol. (2005) 7(7):1009-1017.
64. OWEN SM, RUDOLPH DL, WANG W et al.: RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses (2004) 20(11):1157-1165.
65. VANCOMPERNOLLE SE, TAYLOR RJ, OSWALD-RICHTER K et al.: Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells. J. Virol. (2005) 79(18):11598-11606.
66. LORIN C, SAIDI H, BELAID A et al.: The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology (2005) 334(2):264-275.
67. LUSHBAUGH WB, BLOSSOM AC, SHAH PH et al.: Use of intravaginal microbicides to prevent acquisition of Trichomonas vaginalis infection in Lactobacillus-pretreated, estrogenized young mice. Am. J. Trop. Med. Hyg. (2000) 63(5-6):284-289.
68. OPPENHEIM JJ, YANG D: Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. (2005) 17(4):359-365.
69. DELFINO D, CUSUMANO VV, TOMASELLO F, CUSUMANO V: Beneficial effects of antibacterial peptide PR-39 in a neonatal murine model of endotoxic shock. New Microbiol. (2004) 27(4):369-374.
70. KUROSAKA K, CHEN Q, YAROVINSKY F, OPPENHEIM JJ, YANG D: Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. (2005) 174(10):6257-6265.
71. DAVIDSON DJ, CURRIE AJ, REID GS et al.: The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. (2004) 172(2):1146-1156.
72. SHAYKHIEV R, BEISSWENGER C, KANDLER K et al.: Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 289(5):L842-L848.
73. BRAFF MH, HAWKINS MA, DI NARDO A et al.: Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. (2005) 174(7):4271-4278.
74. CHAVAKIS T, CINES DB, RHEE JS et al.: Regulation of neovascularization by human neutrophil peptides (α-defensins): a link between inflammation and angiogenesis. FASEB J. (2004) 18(11):1306-1308.
75. LEE PH, RUDISILL JA, LIN KH et al.: HB-107, a nonbacteriostatic fragment of the antimicrobial peptide cecropin B, accelerates murine wound repair. Wound Repair Regen. (2004) 12(3):351-358.
76. VARADHACHARY A, WOLF JS, PETRAK K et al.: Oral lactoferrin inhibits growth of established tumours and potentiates conventional chemotherapy. Int. J. Cancer (2004) 111(3):398-403.
77. HAYES TG, FALCHOOK GF, VARADHACHARY GR et al.: Phase I trial of oral talactoferrin alfa in refractory solid tumours. Invest. New Drugs (2005) (In Press).
78. BROUWER CPJ BS, WELLING MM, VELDERS MP, NIBBERING PH The high effective antimicrobial peptide hLF (1-11) may be given to (immunocompromised) mice with a multidrug resistant Staphylococcus aureus infection by various routes. 45th Interscience Conference on Antimicrob. Agents Chemother. Washington DC, USA (2005).
79. DING B, YIN N, LIU Y et al.: Origins of cell selectivity of cationic steroid antibiotics. J. Am. Chem. Soc. (2004) 126(42):13642-13648.
80. KICHLER A, LEBORGNE C, SAVAGE PB, DANOS O: Cationic steroid antibiotics demonstrate DNA delivery properties. J. Control Release (2005) 107(1):174-182.
81. ZASLOFF M: Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad Sci. USA (1987) 84(15):5449-5453.
82. BOWDISH DM, DAVIDSON DJ, LAU YE et al.: Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. (2005) 77(4):451-459.
83. YANG N, STROM MB, MEKONNEN SM, SVENDSEN JS, REKDAL O: The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J. Pept. Sci. (2004) 10(1):37-46.
84. WASILUK KR, LESLIE DB, VIETZEN PS, MAYO KH, DUNN DL: Structure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/ permeability-increasing protein. Surgery (2004) 136(2):253-260.
85. UKNIS ME, WASILUK KR, ACTON RD et al.: Design of a potent novel endotoxin antagonist. Surgery (1997) 122(2):380-385.
86. VAN DER SCHAFT DW, TOEBES EA, HASEMAN JR, MAYO KH, GRIFFIOEN AW: Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood (2000) 96(1):176-181.
87. TEW GN, LIU D, CHEN B et al.: De novo design of biomimetic antimicrobial polymers. Proc. Natl. Acad. Sci. USA (2002) 99(8):5110-5114.
88. GRIECO P, ROSSI C, COLOMBO G et al.: Novel α-melanocyte stimulating hormone peptide analogues with high candidacidal activity. J. Med. Chem. (2003) 46(5):850-855.
89. CATANIA A, GAROFALO L, CUTULI M et al.: Melanocortin peptides inhibit production of pro-inflammatory cytokines in blood of HIV infected patients. Peptides (1998) 19(6):1099-1104.